<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983760</url>
  </required_header>
  <id_info>
    <org_study_id>SPECTACULAR - RB 16.068</org_study_id>
    <nct_id>NCT02983760</nct_id>
  </id_info>
  <brief_title>Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT.</brief_title>
  <acronym>SPECTACULAR</acronym>
  <official_title>Comparison of 3 Diagnostic Strategies of Pulmonary Embolism : Planar Ventilation-perfusion Scintigraphy (Planar V/Q Scan), Computed Tomography Pulmonary Angiography (CTPA), and V/Q Single Photon Emission Computed Tomography (SPECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary embolism (PE) remains a diagnostic challenge. False negative testing exposes
      patient to the risk of potentially fatal recurrence. False positive testing exposes patients
      to potentially fatal unduly side effects of anticoagulants.

      Current diagnostic strategies rely on the sequential use of pretest clinical probability,
      Ddimer test, and chest imaging. Two chest imaging modalities have been validated for PE
      diagnostic exclusion: Computed Tomography Pulmonary Angiography (CTPA) and planar V/Q scan.
      Main limitations of planar V/Q are the high proportion of non-conclusive results, therefore
      requiring additional testing and more complex diagnostic algorithms. Main limitations of CTPA
      are its higher radiation dose and contraindications (renal failure).

      In a randomized trial that compared strategies based on CTPA and on planar V/Q scan, a 30%
      increase in the rate of PE diagnoses was found in the arm using CTPA, raising the hypothesis
      of over-diagnosing and over-treating PE when using CTPA.

      V/Q Single Photon Emission CT (SPECT) is a new method of scintigraphic acquisition that has
      been reported to improve the diagnostic performances of the test, which could reduce the
      number of non-conclusive tests and allow simplified diagnostic algorithms.

      The investigators hypothesize that a strategy based on V/Q SPECT could be an alternative to
      the two usual approaches responding rightly to the two mains issues and combining the
      advantages of CTPA (simplified diagnostic approach) and planar V/Q (no overdiagnosis, lower
      radiation exposure, no contraindication).

      Although a recent survey showed that up to 70% of nuclear medicine centers perform SPECT
      rather than planar imaging for diagnosing PE, a diagnostic management outcome study, in which
      diagnostic decision would be made on the basis of a standardized algorithm based on the V/Q
      SPECT is lacking. Such a study needs to be conducted to ensure that the safety of diagnostic
      exclusion using a V/Q SPECT based strategy is non-inferior to that of previously validated
      strategies, and to verify that the use of V/Q SPECT does not lead to over-diagnosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolic events rate in a 3 month follow-up period in patients left untreated after a negative diagnostic strategy.</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of symptomatic objectively confirmed thromboembolic events during the 3-month follow-up period in patients left untreated after a negative diagnostic work-up in V/Q SPECT-based strategy in comparison with planar V/Q-based strategy and CTPA-based strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of PE diagnostic in each arm</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients deemed to have PE according to the strategy in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of additionnal tests required in each arm</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients for whom additional tests are requested in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding incidence in each arm</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of major bleeding episodes in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and cause of death in each arm</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence and cause of death in each arm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3672</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Planar V/Q-based strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTPA-based strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V/Q SPECT-based strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Planar V/Q-based strategy</intervention_name>
    <description>Strategy based on planar pulmonary scintigraphy</description>
    <arm_group_label>Planar V/Q-based strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CTPA-based strategy</intervention_name>
    <description>Strategy based on pulmonary angiography</description>
    <arm_group_label>CTPA-based strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>V/Q SPECT-based strategy</intervention_name>
    <description>Strategy based on pulmonary tomoscintigraphy</description>
    <arm_group_label>V/Q SPECT-based strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with a clinically suspected PE (defined as an acute onset of new or
             worsening shortness of breath, chest pain, hemoptysis, presyncope, or syncope) without
             another obvious apparent cause.

          -  High pretest clinical probability of PE or a non-high pretest clinical probability but
             a positive D-Dimer test.

        Exclusion Criteria:

          -  Age less than 18 years

          -  Patients with already confirmed PE

          -  Patients with a clinically suspected high-risk pulmonary embolism (hypotension or
             shock)

          -  Use of therapeutic doses of anticoagulants for more than 48 hours

          -  Other indication for long-term use of anticoagulants

          -  Contraindication to contrast media (including renal insufficiency with a creatinine
             clearance lower than 30 ml/min)

          -  Life expectancy less than 3 months

          -  Unable/unwilling to give informed consent

          -  Unlikely to comply with study follow-up

          -  Ongoing pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves Salaun</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Yves Salaun</last_name>
    <phone>0298223117</phone>
    <email>pierre-yves.salaun@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gr√©goire Le Gal</last_name>
    <email>gregoire.legal@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Esprit</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Trinh-Duc</last_name>
      <phone>+33(0)553697093</phone>
      <email>albert.trinh-duc@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Marie ROY</last_name>
      <phone>0141353715</phone>
      <email>pmroy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Yves Salaun</last_name>
      <phone>0298223117</phone>
      <email>pierre-yves.salaun@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H√¥pital des Arm√©es Clermont Tonnerre</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Paleiron</last_name>
      <phone>+33 (0)2 98 43 73 01</phone>
      <email>nicolas.paleiron@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannot Schmidt</last_name>
      <phone>+33(0)473751550</phone>
      <email>jschmidt@chuclermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Falvo</last_name>
      <phone>+33(0)380293409</phone>
      <email>nicolas.falvo@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roge Christophe</last_name>
      <phone>+33 (0)2 98 62 61 60</phone>
      <email>croge@ch-morlaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hegp - Ap-Hp</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-√âtienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Bertoletti</last_name>
      <phone>+33(0)477127770</phone>
      <email>laurent.bertoletti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Elias</last_name>
      <phone>+33(0)494145809</phone>
      <email>antoine.elias@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Gen√®ve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Righini</last_name>
      <phone>+41 (0)22 372 92 94</phone>
      <email>Marc.Righini@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

